• Expanded Phase 2 study confirms consistency and robustness of Vitrafy's cryopreservation approach
• No-wash protocols show comparable or better results than current legacy benchmark
• Final analysis and validation underway, with results expected in Q4 FY2026

Vitrafy Life Sciences Limited (ASX: VFY) has announced the completion of Phase II testing in a platelet cryopreservation study conducted by the U.S. Army Institute of Surgical Research (USAISR). The Phase II study builds on earlier Phase I testing by increasing the number of platelet samples assessed, with the objective of confirming the consistency of earlier results and further characterising performance across multiple cryopreservation formulations. The work forms part of the ongoing Cooperative Research and Development Agreement (CRADA) between Vitrafy and the U.S. Army, which is focused on deploying a rapid response, platelet solution for use in trauma settings. The Phase II study evaluated both a wash-based protocol, representing the current legacy benchmark standard, as well as Vitrafy's no-wash protocols, which enable streamlined cryopreservation and transfusion. Indicative results from the wash-based protocol were consistent with Phase I outcomes, while the no-wash protocols showed comparable or better performance compared to the legacy benchmark. Final analysis and validation are underway, with the final report expected to be released in Q4 FY2026. Vitrafy and USAISR are also preparing to present the findings at international scientific conferences this year, and discussions regarding potential next steps on commercialisation and partnership expansion with the U.S. Army are ongoing.

Vitrafy and USAISR are preparing the Phase II study report, with publication targeted for Q4 FY2026. Both parties intend to present the findings at international scientific conferences this year. Discussions regarding potential next steps on commercialisation and partnership expansion with the U.S. Army are ongoing.